1. Introduction
The traditional organic chemistry synthesis required for the manufacture of pharmaceuticals and fine chemicals often relies on the application of metal-based catalysis as well as petrochemical feedstocks. These resources are often energy intensive and environmentally damaging, both in their application and their extraction [
1]. The use of (waste) CO
2 as a building block to produce high value compounds and pharmaceutical precursors is of considerable interest, given the potential green chemistry credentials of such processes. However, the high-activation-energy barriers of C-H activation, and subsequent carboxylation, present a formidable challenge, requiring high pressures and harsh reaction conditions [
2].
In contrast, biological CO
2 fixation offers a sustainable route to a wide range of compounds, and recent work has identified several enzyme classes capable of C-H activation and (de)carboxylation [
3]. One such class is the UbiD family, a group of enzymes that rely on the modified flavin cofactor prFMN to perform the reversible (de)carboxylation of a range of aromatic and aliphatic poly-unsaturated carboxylic acids [
4]. While the inherent thermodynamics usually strongly favor the decarboxylative reaction [
5,
6], at increased [CO
2] these enzymes can be used to achieve C-H activation through carboxylation at ambient conditions.
In an alternative, bioinspired approach, it has been demonstrated that by coupling this prFMN-dependent class of UbiD (de)carboxylases with carboxylic acid reductase (CAR), it is possible to overcome the inherent thermodynamic bias towards decarboxylation, even at ambient [CO
2]. Indeed, combining fungal Fdc1 with CAR yields carboxylation of terminal alkenes and concomitant reduction of the intermediate carboxylic acids, to produce value-added aldehydes [
7].
However, Fdc1 type enzymes have limited substrate specificity compared to that seen across the collective UbiD family, with a substrate preference largely consisting of cinnamic acid derivatives, or short chain polyunsaturated aliphatic acids [
5]. The varied substrate range of the UbiD family suggests that coupling distinct family members to CAR can offer a putative route to other aldehyde products. The recently characterised
Pseudomonas aeruginosa PA0254 has been shown to catalyse the interconversion of pyrrole and pyrrole-2-carboxylic acid. With the introduction of a single point mutation, it is possible to broaden the substrate scope of PA0254 to include furan and thiophene type substrates [
8].
Five-member heterocyclic aldehydes such as furfural, thiophene-, and pyrrole-2-carbaldehyde have been found to be useful building blocks in the synthesis of high value compounds such as polymers, biochemical dyes, and pharmaceuticals [
9,
10,
11]. For example, pyrrole-2-carbaldehyde has been utilised in the production of the BODIPY family of fluorescent dyes [
9], while furfural has applications in resin production, herbicides, and hypergolic fuels [
10]. Thiophene-2-carbaldehyde has been used in the purification of palladium from aqueous solutions [
11].
Hence, a system coupling PA0254 with a suitable CAR could, in principle, yield valuable heteroaromatic aldehydes and present an attractive route to this class of compounds. However, to our knowledge, no CAR enzyme has been reported to reduce pyrrole-2-carboxylic acid or the furan and thiophene counterparts [
12,
13,
14,
15,
16].
We report that carboxylic acid reductase from
Segniliparus rotundus (CARse) is capable of the reduction of pyrrole-, furan- and thiophene-2-carboxylic acids to their corresponding aldehydes. Furthermore, we demonstrate that coupling with PA0254 supports a one-pot biocatalytic method for the carboxylation and subsequent reduction of pyrrole to form pyrrole-2-carbaldehyde (
Figure 1).
3. Materials and Methods
3.1. Production and Preparation of Active PA0254 Biocatalysts
Heterologous expression and purification of PA0254 was performed as described previously [
8]. Briefly, PA0254 was co-transformed with Pseudomonas aeruginosa UbiX in HMS174(DE3) chemically competent
E. coli (Merck) and expressed in liquid culture via IPTG-mediated induction. The obtained cells were lysed via constant flow cell-disruption, and the active PA0254UbiX was purified from the obtained lysate via nickel-affinity chromatography performed using gravity flow. The purified biocatalyst was desalted to remove imidazole and flash frozen prior to storage at −80 °C. SDS-Page characterisation of purified biocatalysts may be found in
Figure S1.
3.2. Production and Preparation of CARse Biocatalysts
3.2.1. Cloning and Expression
Cloning and expression of CARse was performed, as previously described [
16]. In short, CARse was co-expressed in HMS174(DE3) (Merck), with a sfp-type 4′-phosphopantetheinyl transferase from
Bacillus subtilis in the same manner described for PA0254.
3.2.2. Preparation of Whole-Cell Biocatalyst
Harvested cells were washed by resuspension in sterile chilled phosphate buffered saline (PBS) solution, via gently repeated aspiration with a 50 mL serological pipette, and were transferred to 50 mL conical centrifuge tubes. Suspension was then centrifuged at 3500× g for 15 min, and the supernatant was discarded. This wash step was repeated two further times. The final cell suspension was split into 1 mL aliquots in 1.5 mL microcentrifuge tubes, and cells were harvested via a final centrifugation step and the supernatant discarded. Whole-cell biocatalyst was then either immediately frozen at −20 °C for storage or resuspended in 800 µL of chilled (PBS).
3.2.3. Preparation of Purified Biocatalyst
Harvested cells were resuspended at a 1:4 (wet cell mass:buffer) ratio in 50 mM Tris pH 7.0, 300 mM NaCl, 10 mM imidazole, and 1 mM MgCl
2, supplemented with complete EDTA-free protease inhibitors (Roche), DNase, and RNase (Sigma). Cells were lysed via constant flow cell disruption at 10 kPSi and 20 kPsi, sequentially. Cell lysate was centrifuged at 20,000×
g for 1 h, and the supernatant filter was with a 0.45 µm filter, before application to a gravity flow column containing Ni-NTA (Qiagen) equilibrated in resuspension buffer. Following loading, the column was washed with 10 column volumes of resuspension buffer, followed by 10 column volumes of 50 mM Tris pH 7.0, 300 mM NaCl, and 40 mM imidazole. The desired protein was eluted from the column in the above buffer supplemented with imidazole to 250 mM, analysed for purity via SDS-PAGE, and desalted into 50 mM Tris pH 7.0 and 200 mM NaCl, using a CentriPure P100 gel filtration column (empBiotech). SDS-Page characterisation of purified biocatalysts may be found in
Figure S1.
3.3. Carboxylic Acid Reductase Enzyme Screening
Qualitive screening of CARse against heteroaromatic substrates was performed using purified enzyme at a 500 µL scale. Reactions contained 0.25 mg purified CARse, 5 mM of carboxylic acid substrate, 10 mM each NADPH and ATP, 100 mM MgCl2, and 100 mM Tris pH 7.5. Samples were incubated at 30 °C for 18 h and analysed via HPLC for the desired aldehyde product. Screening was performed in triplicate against pyrrole-2-carboxylic acid, furan-2-carboxylic acid, thiophene-2-carboxylic acid, and benzoic acid substrates.
3.4. Initial PA0254-CARse Coupling Reactions
Reactions contained 100 mM Potassium phosphate buffer pH 6.0, 500 mM Potassium bicarbonate, 10 mM Pyrrole, 0.27 mg/mL and 0.50 mg/mL purified PA0254 and CARse biocatalysts, respectively, of 20 mM ATP (pH 7.0), 20 mM NADPH, and 40 mM MgCl2. Final assay pH was measured at pH 7.4. Assays were performed in triplicate against a biocatalyst free control incubated at 30 °C for 18 h.
3.5. Optimisation of Assay Conditions
3.5.1. Nicotinamide Recycling
Comparison of nicotinamide cofactor recycling was performed as described in the initial coupling reaction, with a reduced NADPH concentration to 0.25 mM, and the addition of 20 mM glucose and 0.30 mg/mL of either purified wildtype glucose dehydrogenase from B. subtilis or a commercially available alternative (CDX-901-CODEXIS).
3.5.2. Bicarbonate Optimization
Bicarbonate concentration assays were performed by incorporating the lowered NADPH concentration of 0.25 mM and the addition of 0.30 mg/mL CDX-901 GDH (Codexis) and 20 mM glucose to the initial coupling reaction conditions. The concentration of potassium bicarbonate was then varied in 100 mM increments between 100 mM and 500 mM, in addition to one condition at 50 mM. The final pH of each condition was measured, as shown in
Table 1. All assays were performed in triplicate in comparison to biocatalyst-free controls and assayed via HPLC.
3.5.3. ATP Recycling
Assays to characterise the effect of the introduction of a two-enzyme recycling system were performed at a 500 µL scale containing 100 mM potassium phosphate pH 6.0, 300 mM KHCO3, 40 mM MgCl2, 20 mM Glucose, 0.27 mg/mL PA0254, 0.50 mg/mL CARse, 0.3 mL CDX-901, and 10 mM pyrrole. In addition, the recycling system consisted of 4.00 mg/mL sodium hexametaphosphate, 0.5 mM ATP (pH 7.0), and 0.25 mg/mL, each purified adenylate kinase (AdK) and polyphosphate:AMP transferase (PAP) from Acinetobacter johnsonii. Assays were performed in triplicate vs an ATP-excess control, which replaced the recycling system with 20 mM ATP (pH 7.0). The final assay pH was measured at pH 7.22.
3.5.4. Whole-Cell CARse Biocatalyst Assays
The effect of the use of CARse whole-cell biocatalysts to enable economical in situ ATP and NADPH production was assessed in the following conditions at a 500 µL scale: 100 mM potassium phosphate pH 6.0, 300 mM KHCO3, 50 mM Glucose, 40 mM MgCl2, 10 mM Pyrrole, 0.27 mg/mL PA0254, and CAR9 whole cells at a final OD600 of 20 or 50. Glycerol supplementation was performed via the addition of 50% sterile glycerol to 5%, 10%, or 15% final volume.
3.5.5. Pyrrole-2-carboxaldehyde Degradation Assay
To assess the stability of pyrrole-2-carboxaldehyde over time, freshly prepared 0.5, 1.0, and 2.0 mM stocks of the aldehyde were prepared in 100 mM KPi pH 6.0, 300 mM KHCO3, 50 mM Glucose, and 40 mM MgCl2, and the peak response area was determined via HPLC. Identical stocks were, concurrently, prepared in the same buffer and incubated at 30 °C for 18 h, both with and without the addition of 0.27 mg/mL purified PA0254 and whole-cell CARse biocatalyst, to a final OD600 of 20. Peak area response was then determined via HPLC, as previously performed. All conditions were prepared in triplicate.
3.6. Analytical Procedures
All samples were analysed on an Agilent 1260 Infinity HPLC equipped with an Ascentis C18 581325-U (Supelco) or a Kinetex 00G-4601-E0 column (Phenomenex). The mobile phase consisted of varying ratios of water and acetonitrile modified with 0.1% v/v TFA, as described below. The quantification of aldehyde products was assessed via comparison to peak area response of analytical standard at varying concentration.
PA0254-CAR coupling reactions utilising pyrrole were extracted via the addition of 500 µL of MTBE, brief vortexing, incubation at 30 °C for 5 min, and centrifugation at 15,000× g for 30 min at 4 °C. The organic layer was then removed and analysed via HPLC, utilising a 50:50 ACN:H2O isocratic method for 6 min at a 1 mL/min flow rate monitored at 290 nm.
Reactions utilising thiophene and 3-methylfuran substrates were quenched via the addition of 1 reaction volume of acetonitrile supplemented with 0.1% v/v trifluoracetic acid. Samples were then incubated at 30 °C for 5 min, before centrifugation at 15,000× g for 30 min at 4 °C. Thiophene samples were analysed using a 10 min 60:40 ACN:H2O isocratic method and monitored at 240 nm, while 3-methylfuran was analysed at 50:50 ACN:H2O over the same time period and monitored at 220 nm.
4. Conclusions
We conclude that an optimised PA0254-CARse one-pot reaction system is capable of carboxylation of pyrrole to pyrrole-2-carbaldehyde, but it suffers from low yield due to the instability of the target product. Similar observations of aldehyde instability in biocatalytic systems have been made, when coupling CAR enzymes with the prFMN-dependent indole-3-decarboxylase from
Arthrobacter nicotianae [
21], which noted the degredation of indole-3-carboxaldehyde product following extended incubaiton. This further highlights the applicability of a linked UbiD-CAR system, though future work may improve on this system in the stabilization or scavenging of the aldehyde, either via enzymatic means such as linkage to an imine reductase for the production of allylic amines, as previously described in the further modification of UbiD-CAR-produced cinnamaldehyde with
Cystobacter ferrugineus imine reductase to produce
N-cinnamylcyclopropylamine [
7], or via methods of in situ product recovery such as biphasic reactions [
22]. However, this work provides proof of principle of an efficient biosynthetic toolkit to produce heteroaromatic aldehydes and may be applied in future in the biological synthesis of their derivatives (
Figure 10). Furthermore, it demonstrates that the relatively broad natural substrate specificity of the UbiD, and CAR enzyme families can be harnessed to deliver a route to a range of aldehydes, by tailoring the enzyme combination to ensure efficient CO
2 fixation.